So They Say

Verbatim excerpts from the media on the conduct of science. Underwriting Science "I think it's probably true that we've been living off the investments we made in technology years ago," says Sally Ride, the young astronaut who became highly visible in the agency's [NASA's] management after serving as a member of the Rogers Commission. "We've recognized this in the last year, and realized the need for NASA to start investing again in basic R&D…." Other observers wonder whether Star Wars wil

| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Other observers wonder whether Star Wars will replace space exploration as the government's principal means for funneling tax dollars into technology. "The role of government is to build technological infrastructures, which should be flexible at the leading edge,' says Jerome Simonoff, a Citicorp vice president who specializes in aerospace investment. He hypothesizes that no one, except maybe the President, believes SDI will actually work. But he says it represents the only consensus on how to underwrite expensive high-tech science.

Our experience suggests that the scientific community is not yet willing to evaluate and remedy its shortcomings. Scientific research is expensive, and the public pays for most of it, particularly in the health sciences, where a defective article can have particularly destructive consequences. Scientists have an obligation to make sure that published research is actually what it claims to be. Scientists should find out how common professional misconduct really is Then ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies